AMG-337

Known as: AMG 337, AMG337, c-Met Inhibitor AMG 337 
An orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2016
012320132016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
AMG 337, a selective small-molecule MET inhibitor, was evaluated in Asian patients with advanced solid tumors. Eligible patients… (More)
  • table 1
  • table 2
Is this relevant?
2017
2017
Therapeutic resistance is a major obstacle to achieving durable clinical responses with targeted therapies, highlighting a need… (More)
Is this relevant?
2016
2016
The MET receptor tyrosine kinase is involved in cell growth, survival, and invasion. Clinical studies with small molecule MET… (More)
Is this relevant?
2016
2016
Aberrant hepatocyte growth factor (HGF)/MET signaling has been implicated in hepatocarcinogenesis, suggesting that MET may serve… (More)
Is this relevant?
2016
2016
Deregulation of the receptor tyrosine kinase mesenchymal epithelial transition factor (MET) has been implicated in several human… (More)
Is this relevant?
2013
2013
The study reported in the article by Smith et al that accompanies this editorial presents data on a novel orally bioavailable… (More)
Is this relevant?